ORCL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Oracle Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Oracle Corporation · Technology
$184.31
+14.0% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
ORCL has more upside to fair value
(+14.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ORCL |
PFE |
| Current Price |
$184.31 |
$25.22 |
| Fair Value Estimate |
$210.13 |
$25.92 |
| Upside to Fair Value |
+14.0%
|
+2.8%
|
| Market Cap |
$530.1B |
$143.7B |
| Forward P/E |
31.0x
|
19.2x
|
| EV / EBITDA |
20.4x
|
12.3x
|
| Price / Sales |
7.9x
|
2.3x
|
| Price / FCF |
-22.4x
|
15.2x
|
| Revenue Growth YoY |
+20.6%
|
+5.4%
|
| Gross Margin |
65.8%
|
69.3%
|
| Operating Margin |
30.8%
|
23.4%
|
| Return on Equity |
50.4%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Oracle Corporation is a leading enterprise software and cloud infrastructure provider with a durable competitive moat driven by its extensive software portfolio, strong cloud growth, and stable leadership. The company reported $57.4 billion in revenue for fiscal 2025, growing 8% year-over-year, with cloud services and license support growing 12%. Oracle's cloud infrastructure (OCI) is a key growt…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
ORCL |
PFE |
| Zone Low |
$157.60 |
$19.44 |
| Zone High |
$178.61 |
$22.03 |
| In Buy Zone? |
No
|
No
|